2-[8-methoxy-2-(trifluoromethyl)quinolin-5-yl]-5-[(1S)-1-[(2-methylpropan-2-yl)oxycarbonylamino]ethyl]-1,3-oxazole-4-carboxylic acid | 871002-41-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: 2-[8-methoxy-2-(trifluoromethyl)quinolin-5-yl]-5-[(1S)-1-[(2-methylpropan-2-yl)oxycarbonylamino]ethyl]-1,3-oxazole-4-carboxylic acid
• CAS: 871002-41-4
• 化学式: C₂₂H₂₂F₃N₃O₆
• 分子量: 481.428
• InChiKey: IRCKCABXDZHPCF-JTQLQIEISA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4
• 重原子数：
  34
• 可旋转键数：
  7
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  124
• 氢给体数：
  2
• 氢受体数：
  11

反应信息

• 作为反应物：
  描述：

  2-[8-methoxy-2-(trifluoromethyl)quinolin-5-yl]-5-[(1S)-1-[(2-methylpropan-2-yl)oxycarbonylamino]ethyl]-1,3-oxazole-4-carboxylic acid 在 盐酸 、 N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate 作用下， 以 1,4-二氧六环 、 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 生成 [5-[(1S)-1-aminoethyl]-2-[8-methoxy-2-(trifluoromethyl)quinolin-5-yl]-1,3-oxazol-4-yl]-pyrrolidin-1-ylmethanone
  参考文献：
  名称：

  Discovery of oral and inhaled PDE4 inhibitors

  摘要：

  The optimization of oxazole-based PDE4 inhibitor 1 has led to the identification of both oral (compound 16) and inhaled (compound 34) PDE4 inhibitors. Selectivity against PDE10/PDE11, off target screening, and in vivo activity in the rat are discussed. (C) 2013 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2013.08.056
• 作为产物：
  描述：

  ethyl 2-[8-methoxy-2-(trifluoromethyl)quinolin-5-yl]-5-[(1S)-1-[(2-methylpropan-2-yl)oxycarbonylamino]ethyl]-1,3-oxazole-4-carboxylate 在 水 、 sodium hydroxide 、 盐酸 作用下， 以 四氢呋喃 、 乙醇 、 水 为溶剂， 反应 5.5h， 以90%的产率得到2-[8-methoxy-2-(trifluoromethyl)quinolin-5-yl]-5-[(1S)-1-[(2-methylpropan-2-yl)oxycarbonylamino]ethyl]-1,3-oxazole-4-carboxylic acid
  参考文献：
  名称：

  HYDROGEN CHLORIDE SALT OF A SUBSTITUTED 5-OXAZOL-2-YL-QUINOLINE COMPOUND AND A PROCESS FOR THE PRODUCTION THEREOF

  摘要：

  该发明涉及化合物的公式I：以及使用该化合物治疗上呼吸道和下呼吸道梗阻性疾病的方法，包括该化合物的配方，特定的晶体形式以及合成晶体形式的过程。IM=105109

  公开号：

  US20110003780A1

文献信息

• Process and intermediates for the synthesis of 2-(quinolin-5-yl)-4,5 disubstituted-azole derivatives
  申请人：Cutarelli D. Timothy

  公开号：US20080045718A1

  公开（公告）日：2008-02-21

  This application discloses a novel process to synthesize 2-(Quinolin-5yo)-4,5-Disubstituted-Azole derivatives, which may be used, for example, as PDE IV inhibitor compounds in pharmaceutical preparations.

  这项申请揭示了一种合成2-(喹啉-5-基)-4,5-二取代-咪唑衍生物的新工艺，该衍生物可以用作制药制剂中的PDE IV抑制剂化合物。
• [EN] SUBSTITUTED 2-QUINOLYL-OXAZOLES USEFUL AS PDE4 INHIBITORS<br/>[FR] 2-QUINOLYLE-OXAZOLES SUBSTITUÉS UTILES COMME INHIBITEURS DU PDE4
  申请人：SCHERING CORP

  公开号：WO2005116009A1

  公开（公告）日：2005-12-08

  The invention claims compounds of the: (formula I); wherein: (formula II) is a 5-membered heteroaryl; X is S or O; R1 is H, alkyl, cycloalkyl, cylcoalkylalkyl-, -CH2F, -CHF2, -CF3, -C(O)alkyl or -C(O)NR18R19; R3 and R4 H, alkyl, hydroxyalkyl or -C(O)Oalkyl; R5 and R6 are H, alkyl, hydroxyalkyl, alkoxyalkyl, mercaptoalkyl, -CH2F, -CHF2, -CF3, -C(O)OH or -C(O)Oalkyl; R7 is H, alkyl, alkenyl, hydroxyalkyl, cycloalkyl, alkoxyalkyl, aminoalkyl, (R17-phenyl)alkyl or -CH2-C(O)-O-alkyl; and R8 comprises alkyl, heteroaryl, phenyl or cycloalkyl, or heterocycloalkyl, all optionally substituted, or a cycloalkyl- or heterocycloalkyl-substituted amide; or R7 and R8 and the nitrogen to which they are attached together form an optionally substituted ring; and the remaining variables are as defined in the specification. Also claimed are pharmaceutical compositions, the use of the compounds as PDE4 inhibitors, and combinations with other actives.

  该发明声明了以下化合物：(化学式I)；其中：(化学式II)是一种5-成员杂环芳基；X为S或O；R1为H，烷基，环烷基，环烷基烷基，-CH2F，-CHF2，-CF3，-C(O)烷基或-C(O)NR18R19；R3和R4为H，烷基，羟基烷基或-C(O)O烷基；R5和R6为H，烷基，羟基烷基，烷氧基烷基，巯基烷基，-CH2F，-CHF2，-CF3，-C(O)OH或-C(O)O烷基；R7为H，烷基，烯基，羟基烷基，环烷基，烷氧基烷基，氨基烷基，(R17-苯基)烷基或-CH2-C(O)-O-烷基；R8包括烷基，杂环芳基，苯基或环烷基，或杂环烷基，均可选择性取代，或环烷基或杂环烷基取代的酰胺；或R7和R8及它们附着的氮一起形成一个可选择性取代的环；其余变量如规范中所定义。还声明了药物组合物，将这些化合物用作PDE4抑制剂，并与其他活性物质组合使用。
• A process for preparing a substituted oxazole
  申请人：Schering Corporation

  公开号：EP2385050A1

  公开（公告）日：2011-11-09

  A process for producing a compound of formula ID: where R1 is haloalkyl, R2 and R4 are alkyl, R5 is generally hydrogen or alkyl and R6 is an acid labile group, by reacting a compound containing a substituent -C(R3X)NCH2C(O)OR4, where R3 is hydrogen or alkyl and X is O or S, with an alkali metal amide base and a compound R6NHCH(R5)C(O)R7 where R7 is an activated acid moiety.

  一种生产式 ID 化合物的工艺： 其中 R1 为卤代烷基，R2 和 R4 为烷基，R5 一般为氢或烷基，R6 为易受酸作用的基团，其方法是将含有取代基-C(R3X)NCH2C(O)OR4（其中 R3 为氢或烷基，X 为 O 或 S）的化合物与碱金属酰胺基和化合物 R6NHCH(R5)C(O)R7（其中 R7 为活化的酸分子）反应。
• Process for making a substituted oxazole
  申请人：Schering Corporation

  公开号：EP2385051A1

  公开（公告）日：2011-11-09

  A process for making a compound of formula IXab: by reacting an anhydride with a compound containing the group -C(SCH3)NCH2CO2Et to produce an oxazole ester, hydrolysing the ester and reacting with an appropriately protected amino salt to give the desired compound.

  一种制造式 IXab 化合物的工艺： 将酸酐与含有基团-C(SCH3)NCH2CO2Et 的化合物反应生成噁唑酯，水解该酯并与适当保护的氨基盐反应得到所需的化合物。
• Discovery of oxazole-based PDE4 inhibitors with picomolar potency
  作者：Rongze Kuang、Ho-Jane Shue、Li Xiao、David J. Blythin、Neng-Yang Shih、Xiao Chen、Danlin Gu、John Schwerdt、Ling Lin、Pauline C. Ting、Jianhua Cao、Robert Aslanian、John J. Piwinski、Daniel Prelusky、Ping Wu、Ji Zhang、Xiang Zhang、Chander S. Celly、Motasim Billah、Peng Wang

  DOI：10.1016/j.bmcl.2012.01.115

  日期：2012.4

  Optimization of oxazole-based PDE4 inhibitors has led to the discovery of a series of quinolyl oxazoles, with 4-benzylcarboxamide and 5-alpha-aminoethyl groups which exhibit picomolar potency against PDE4. Selectivity profiles and in vivo biological activity are also reported. (C) 2012 Elsevier Ltd. All rights reserved.